PCSK9 Antibodies Treatment Specifically Enhances the Macrophage-specific Reverse Cholesterol Transport Pathway in Heterozygous Familial Hypercholesterolemia

PCSK9 inhibitors alter the distribution of macrophage-derived cholesterol within lipoproteins in plasma from heterozygous FH subjects during ex vivo cholesterol efflux, reducing LDL's capacity as a cholesterol acceptor while enhancing HDL's acceptor function.PCSK9 inhibition enhances the macrophage-specific reverse cholesterol transport pathway in human apoB100 transgenic mice, specifically under conditions of heterozygous LDL receptor deficiency.Anti-PCSK9 therapy facilitates the transfer of LDL-derived cholesterol to feces in heterozygous LDLR-deficient mice expressing human APOB100.